Sumitomo Pharma Co., Ltd.
4506
Pozycja w akcjach
#3222
Sumitomo Pharma Co., Ltd. is a global company involved in the creation,... Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Cena akcji
$12.27
Kapitalizacja rynkowa
$5.51B
Zmiana (1 dzień)
2.20%
Zmiana (1 rok)
6.72%
Kraj
JP
Handel Sumitomo Pharma Co., Ltd. (4506)
Kategoria
Healthcare
Marża operacyjna dla Sumitomo Pharma Co., Ltd. (4506)
Marża operacyjna na dzień October 2026 TTM: 10.05%
Według najnowszych raportów finansowych i ceny akcji Sumitomo Pharma Co., Ltd., bieżąca marża operacyjna (TTM) wynosi 10.05%. Na koniec 2024 wynosiła -112.60%.
Historia marży operacyjnej dla Sumitomo Pharma Co., Ltd. od 2005 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 10.05% | 39.20% |
| 2025 | 7.22% | -106.41% |
| 2024 | -112.60% | 712.41% |
| 2023 | -13.86% | -228.81% |
| 2022 | 10.76% | -22.03% |
| 2021 | 13.80% | -19.95% |
| 2020 | 17.24% | 36.83% |
| 2019 | 12.60% | -33.30% |
| 2018 | 18.89% | 47.35% |
| 2017 | 12.82% | 39.96% |
| 2016 | 9.16% | 46.09% |
| 2015 | 6.27% | -42.32% |
| 2014 | 10.87% | 50.97% |
| 2013 | 7.20% | 23.71% |
| 2012 | 5.82% | -28.68% |
| 2011 | 8.16% | -32.11% |
| 2010 | 12.02% | 1.86% |
| 2009 | 11.80% | -21.75% |
| 2008 | 15.08% | -13.53% |
| 2007 | 17.44% | 48.43% |
| 2006 | 11.75% | 77.49% |
| 2005 | 6.62% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -97.72% |
IN
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.